Compare PBH & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBH | CELC |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | 2004 | 2017 |
| Metric | PBH | CELC |
|---|---|---|
| Price | $55.21 | $125.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $75.33 | ★ $112.56 |
| AVG Volume (30 Days) | 490.0K | ★ 665.8K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.88 | N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $975,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.31 | $720.19 |
| P/E Ratio | $20.27 | ★ N/A |
| Revenue Growth | ★ 36.77 | N/A |
| 52 Week Low | $51.24 | $9.64 |
| 52 Week High | $88.00 | $129.09 |
| Indicator | PBH | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | 57.27 |
| Support Level | $51.24 | $100.58 |
| Resistance Level | $63.56 | N/A |
| Average True Range (ATR) | 1.84 | 7.28 |
| MACD | 0.09 | -0.10 |
| Stochastic Oscillator | 12.34 | 86.78 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.